Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q1 2020 · 10-Q
Revenue$14.35M$14.35M+42.8% vs Q1 2019 Net Income-$5.90M-$5.90MN/M vs Q1 2019 EPS Diluted-$0.10-$0.10N/M vs Q1 2019 Gross Profit$8,311,000+56.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flow-$5,221,000N/M Free Cash Flowderived-$5,236,000N/M Margins · derivedGross margin57.9%+5.2 pt vs Q1 2019
Operating margin-41.1%+42.3 pt vs Q1 2019
Net margin-41.1%+41.8 pt vs Q1 2019
ended Mar 31, 2020 · filed May 18, 2020 · 48 d after period end